Table 2 Most frequently observed treatment-emergent adverse events^a.

Treatment-emergent adverse event (AE)	Severity								Total
	Grade 1–2				Grade 3				Total
	Events		Patients		Events		Patients		Events (N = 505)		Patients (N = 52)
Hyperphosphataemia	43	8.5%	26	50%	0		0		43	8.5%	26	50%
Dry mouth	29	5.7%	23	44%	0		0		29	5.7%	23	44%
Alopecia	23	4.6%	20	38%	0		0		23	4.6%	20	38%
Dysgeusia	15	3.0%	13	25%	0		0		15	3.0%	13	25%
Constipation	12	2.4%	12	23%	0		0		12	2.4%	12	23%
Nausea	14	2.8%	12	23%	0		0		14	2.8%	12	23%
Retinal pigment epithelium detachment (RPED)	16	3.2%	11	21%	0		0		16	3.2%	11	21%
Diarrhoea	16	3.2%	10	19%	0		0		16	3.2%	10	19%
Dyspepsia	14	2.8%	10	19%	0		0		14	2.8%	10	19%
Decreased appetite	14	2.8%	8	15%	0		0		14	2.8%	8	15%
Dry eye	9	1.8%	8	15%	0		0		9	1.8%	8	15%
Dry skin	9	1.8%	8	15%	0		0		9	1.8%	8	15%
Epistaxis	11	2.2%	8	15%	0		0		11	2.2%	8	15%
Stomatitis	10	2.0%	8	15%	0		0		10	2.0%	8	15%
Alanine aminotransferase increased	11	2.2%	7	13%	0		0		11	2.2%	7	13%
Aspartate aminotransferase increased	9	1.8%	6	12%	1	0.2%	1	2%	10	2.0%	7	13%
Blood calcium increased	9	1.8%	7	13%	0		0		9	1.8%	7	13%
Calcium phosphate product increased	11	2.2%	7	13%	0		0		11	2.2%	7	13%
Fatigue	12	2.4%	7	13%	1	0.2%	1	2%	13	2.6%	7	13%
Nail disorder	7	1.4%	7	13%	0		0		7	1.4%	7	13%
Onycholysis	6	1.2%	6	12%	0		0		6	1.2%	6	12%
Arthralgia	5	1.0%	5	10%	0		0		5	1.0%	5	10%
Blood albumin decreased	12	2.4%	5	10%	0		0		12	2.4%	5	10%
Blood alkaline phosphatase increased	5	1.0%	4	8%	1	0.2%	1	2%	6	1.2%	5	10%
Glossodynia	5	1.0%	5	10%	0		0		5	1.0%	5	10%
Lethargy	5	1.0%	5	10%	1	0.2%	1	2%	6	1.2%	5	10%
Mouth ulceration	13	2.6%	5	10%	0		0		13	2.6%	5	10%
Vomiting	6	1.2%	5	10%	0		0		6	1.2%	5	10%
Any treatment-emergent AE^b	496	98.2%	50	96%	7	1.4%	6	12%	505	100%	50	96%

^aTreatment-emergent adverse events (AEs) occurring at any time point, in at least 10% of patients and are categorised as “definitely”, “possibly” or “probably” related to the study treatment. Out of the 822 AEs experienced by 52 study participants, 505 are classified as treatment-emergent AEs. There are study participants with repeated or multiple adverse events. Source data are provided as a Source Data file.
^bThere are 2 adverse events out of the total 505 treatment-emergent adverse events without severity grading. The severity of treatment-emergent AEs observed are only from grades 1–3. Of the 52 patients who reported experiencing AEs, 50 of them had treatment-emergent AE

Search